Medical Affairs

Marinus is committed to advancing science and research in a range of seizure disorders, and having a positive impact on the lives of patients and caregivers. We strive to develop safe, effective, and innovative therapies, and provide support and education to the rare disease community.

Learn more about the ways that Marinus is shaping the future of treatments for seizure disorders

Marinus is planning to offer the following programs to further support patients affected by seizure disorders.

Icon Beaker

Educational Grants

Dedication to improving the lives of patients and caregivers

Icon Brain 2

Compassionate Use

We take our responsibility to act as a true partner with the medical community very seriously and are committed to ensuring our innovations reach as many patients as possible, as quickly as possible.

Icon Book

Support & Sponsorship

Supporting activities and programs focused on seizure disorders

BIO Guiding Principles for Interaction with Patient Advocacy Organizations

At Marinus, integrity and trust are of the utmost importance. That is why we abide by BIO patient engagement principles as we work with patient advocacy organizations to better support the patients we serve, and to help raise awareness and understanding of the unmet needs we work to address. You can learn more about these principles here.

BIO guiding principles

Educational Resources

Multi Ethnic Group Of Nursing Students In Class

Kapur et al. 2019 Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus

Holtkamp et al. 2005 Predictors and Prognosis of Refractory Status Epilepticus
Treated in a Neurological Intensive Care Unit

Hocker et al. 2013 Predictors of Outcome in Refractory Status Epilepticus

Chamberlain et al. 2020 Efficacy of levetiracetam, fosphenytoin, and valproate for
established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial

Saporito et al. 2019 Intravenously Administered Ganaxolone Blocks DiazepamResistant Lithium-Pilocarpine–Induced Status Epilepticus in Rats: Comparison with Allopregnanolones

Background on CDKL5 Deficiency Disorder

Amin et al. 2022International Consensus Recommendations for the Assessment and Management of Individuals With CDKL5 Deficiency Disorder

Olson et al. 2019 Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review

Demarest et al. 2019 CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development

Background on Tuberous Sclerosis Complex

Di Michele et al. 2003 GABAA receptor active steroids are altered in epilepsy patients with tuberous sclerosis

To contact medical information, report an adverse event, or product quality complaint, please contact Marinus Medical Information at or call 1-844-MARINUS.